JP2022520088A5 - - Google Patents

Info

Publication number
JP2022520088A5
JP2022520088A5 JP2021547170A JP2021547170A JP2022520088A5 JP 2022520088 A5 JP2022520088 A5 JP 2022520088A5 JP 2021547170 A JP2021547170 A JP 2021547170A JP 2021547170 A JP2021547170 A JP 2021547170A JP 2022520088 A5 JP2022520088 A5 JP 2022520088A5
Authority
JP
Japan
Prior art keywords
pnad
antibody
acid sequence
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547170A
Other languages
English (en)
Japanese (ja)
Other versions
JP7588080B2 (ja
JP2022520088A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017879 external-priority patent/WO2020167912A1/en
Publication of JP2022520088A publication Critical patent/JP2022520088A/ja
Publication of JP2022520088A5 publication Critical patent/JP2022520088A5/ja
Application granted granted Critical
Publication of JP7588080B2 publication Critical patent/JP7588080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547170A 2019-02-13 2020-02-12 抗末梢リンパ節アドレッシン抗体およびその使用 Active JP7588080B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804797P 2019-02-13 2019-02-13
US62/804,797 2019-02-13
PCT/US2020/017879 WO2020167912A1 (en) 2019-02-13 2020-02-12 Anti-peripheral lymph node addressin antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2022520088A JP2022520088A (ja) 2022-03-28
JP2022520088A5 true JP2022520088A5 (cg-RX-API-DMAC10.html) 2023-02-21
JP7588080B2 JP7588080B2 (ja) 2024-11-21

Family

ID=71945935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547170A Active JP7588080B2 (ja) 2019-02-13 2020-02-12 抗末梢リンパ節アドレッシン抗体およびその使用

Country Status (11)

Country Link
US (3) US11028176B2 (cg-RX-API-DMAC10.html)
EP (1) EP3924386A4 (cg-RX-API-DMAC10.html)
JP (1) JP7588080B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210126078A (cg-RX-API-DMAC10.html)
CN (1) CN113795513B (cg-RX-API-DMAC10.html)
AU (1) AU2020221821A1 (cg-RX-API-DMAC10.html)
CA (1) CA3130103A1 (cg-RX-API-DMAC10.html)
IL (1) IL285409A (cg-RX-API-DMAC10.html)
MX (1) MX2021009662A (cg-RX-API-DMAC10.html)
SG (1) SG11202108560RA (cg-RX-API-DMAC10.html)
WO (1) WO2020167912A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009662A (es) 2019-02-13 2021-09-08 Brigham & Womens Hospital Inc Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.
CN119306830B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗皮质醇抗体、检测皮质醇的试剂和试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
IL98744A0 (en) 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
RO120148B1 (ro) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
JP5064612B2 (ja) 1999-04-09 2012-10-31 エーエムエージー ファーマシューティカルズ,インコーポレイテッド 還元された炭水化物類及び炭水化物誘導体で被覆された熱的に安定なコロイド状酸化鉄
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US7060121B2 (en) 2003-06-25 2006-06-13 Hsing Kuang Lin Method of producing gold nanoparticle
CA2473429A1 (en) 2003-07-09 2005-01-09 National Research Council Of Canada Process for producing gold nanoparticles
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2006041613A2 (en) 2004-10-05 2006-04-20 Nanomega Medical Corporation Nanoparticles for targeting hepatoma cells
US7291598B2 (en) 2005-01-04 2007-11-06 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20080166706A1 (en) 2005-03-30 2008-07-10 Jin Zhang Novel gold nanoparticle aggregates and their applications
WO2007033090A2 (en) * 2005-09-13 2007-03-22 The Research Foundation Of State University Of New York At Buffalo Method for diagnosis of chronic allograft rejection
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
CN101679021B (zh) 2007-03-02 2014-04-30 伊利诺伊大学评议会 药物颗粒送递
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US9096660B2 (en) * 2010-04-26 2015-08-04 Abraxis Bioscience, Llc SPARC binding antibodies and uses thereof
WO2015108783A1 (en) 2014-01-16 2015-07-23 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
EP3166627A1 (en) * 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
MX2021009662A (es) 2019-02-13 2021-09-08 Brigham & Womens Hospital Inc Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.

Similar Documents

Publication Publication Date Title
CN111944050B (zh) 一种抗b7-h3抗体及其应用
US12221462B2 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells
CN109310764B (zh) 高亲和力b7-h6抗体和抗体片段
JP2021515568A5 (cg-RX-API-DMAC10.html)
JP2021533726A5 (cg-RX-API-DMAC10.html)
JP2021516975A5 (cg-RX-API-DMAC10.html)
JP2021516974A5 (cg-RX-API-DMAC10.html)
JP2021530987A5 (cg-RX-API-DMAC10.html)
JP2021516976A5 (cg-RX-API-DMAC10.html)
CN116789832A (zh) 抗4-1bb抗体及其制备和使用方法
AU2020298324A1 (en) Anti-TIGIT antibodies
CA3114467C (en) Anti pd-l1 antibody and use thereof
CN118987201A (zh) 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合
CN116801889A (zh) 包含具有多特异性抗体的离体武装t细胞的组合物和其用途
JP2023089245A5 (cg-RX-API-DMAC10.html)
WO2011109662A1 (en) Monoclonal antibodies directed to cd52
JP2024038034A (ja) 膀胱癌の抗pd-l1抗体治療
JP2023536631A5 (cg-RX-API-DMAC10.html)
Salah et al. Targeted therapies: The role of monoclonal antibodies in disease management
CN116535509B (zh) 抗CD79b抗体、其制备方法及其应用
Zhang et al. Advances of bispecific antibodies using/application in dermatology: a review
Niehues Therapeutic monoclonal antibodies as immunomodulators and anti-cancer agents: development, evidence of efficacy, mechanisms of actions, adverse effects
CN114616245A (zh) 一种抗cd38的抗体及其用途
WO2026035616A1 (en) Combinations for the treatment of cancer
WO2026052074A1 (zh) 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用